---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-012938"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T18:22:14.887008+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix Q1 net loss widens to $5.0M; cash $47.5M extends runway to Q2 2024

## Summary
- Net loss of $5.0M ($1.51 per share) vs $4.1M loss in Q1 2021; revenue fell to $1.2M from $1.4M.
- Ended Q1 with $47.5M cash; cash runway extended into Q2 2024, through Pulmazole Phase 2b data readout.
- Pulmazole Phase 2b on track to start dosing Q1 2023; top-line data expected Q2 2024.
- PUR3100 Phase 1 top-line data expected in Q4 2022 from Australian study.
- Completed 1-for-20 reverse stock split and regained Nasdaq compliance in March 2022.

## SEC filing metadata
- accession: 0001493152-22-012938
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315222012938/0001493152-22-012938-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315222012938/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-012938
- JSON: https://secwatch.observer/filing/0001493152-22-012938.json
- Plain text: https://secwatch.observer/filing/0001493152-22-012938.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.